More Mesoblast Limited news
Mesoblast LimitedASX: MSB

MPCs Strengthen Cardiac Function in End-Stage Heart Failure

Mar 30, 2016 at 4:09 AM EDT · Issued by Mesoblast Limited

Filed with ASX · Mar 30, 2016 at 4:09 AM EDT

On 6ix: 6ix.com/news/mpcs-strengthen-cardiac-function-in-end-stage-heart-failure

View Attachment

6ix hasn’t read this filing yet.

Mesoblast Limited on 6ix

Earlier from Mesoblast

  • MSB & NIH Agree 120 Patient Trial In End-Stage Heart FailureMar 30, 2016
  • MSB Accelerates Plans for Commercial Manufacturing OperationMar 30, 2016
  • Mesoblast Receives $5.05m for Stem Cell Pipeline DevelopmentMar 30, 2016
  • Circulation Publishes Improved Outcomes with Mesoblast CellsMar 30, 2016

Later from Mesoblast

  • Half-Year Results & Strategic Update on Product DevelopmentMar 30, 2016
  • Key mpc patents granted in united states and chinaMar 30, 2016
  • Mesoblast Corporate Overview - CEO Message to AGMMar 30, 2016
  • MSB Provides Corporate Strategy For Neurologic ProductMar 30, 2016
  • Positive Results in Phase 2 Lumbar Spinal Fusion TrialMar 30, 2016
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer